Taysha Gene Therapies Retained Earnings (Accumulated Deficit) 2020-2024 | TSHA

Taysha Gene Therapies retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Taysha Gene Therapies Retained Earnings (Accumulated Deficit) 2020-2024 | TSHA

Taysha Gene Therapies retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
BridgeBio Pharma (BBIO)$5B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M